The pharmaceutical group extends its October rebound in a well-oriented Parisian market. The stock climbs to the top of its recent levels and ranks among the leaders of the index, after a month of strong recovery.
A 250-session high that turns the former level into support
The stock rises 1.78% to €88.15 intraday, the fourth-best performance in the CAC 40, which gains 0.79%. It broke above its 250-session high of €86.61, which has now become support.
The gain reaches 23.25% over one month and 4.82% over the week, and the price sits well above the MM200 (+14.66% gap).
The RSI at 83 signals a pronounced overbought configuration, a configuration signal rather than a prediction. The next round level lies at €90. As a reminder, the raising of the 2026 targets after the third quarter was announced on October 30.
A stock trading at nearly ten times the expected earnings of the current year
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
According to the consensus of the analysts surveyed, Sanofi trades at about 9.8 times current-year earnings and 9.5 times next year's, with expected earnings per share growth of 3.8%.
The group has also bought back €1.4 billion of shares over twelve months, or 1.4% of its market capitalization (latest declaration read on April 28, 2026). Over one year, the stock remains at -1.01%, despite the rebound of recent weeks. The analysts' opinion on the stock is available in detail. In the same market, Nanobiotix gains 2.20%, while Eurofins Scientific falls 0.18%.
SectorPharmacie et biotechnologies›Pharmacie, vaccins et santé animale
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 36 550 millions d'euros
Quarterly revenue: 36 550 millions d'euros
Revenue growth: 13,1 %
Net income: 4 979 millions d'euros
Free cash flow: 6 993 millions d'euros
12 201 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
